"Raltegravir Potassium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
| Descriptor ID |
D000068898
|
| MeSH Number(s) |
D03.383.773.812.752
|
| Concept/Terms |
MK 0518- MK 0518
- 0518, MK
- MK0518
- MK-0518
|
Below are MeSH descriptors whose meaning is more general than "Raltegravir Potassium".
Below are MeSH descriptors whose meaning is more specific than "Raltegravir Potassium".
This graph shows the total number of publications written about "Raltegravir Potassium" by people in this website by year, and whether "Raltegravir Potassium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 17 | 5 | 22 |
| 2018 | 7 | 4 | 11 |
| 2019 | 4 | 3 | 7 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Raltegravir Potassium" by people in Profiles.
-
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomed Pharmacother. 2021 Jun; 138:111544.
-
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection. Transpl Infect Dis. 2021 Apr; 23(2):e13500.
-
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Eur J Pharmacol. 2021 Jan 05; 890:173720.
-
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health. 2020 Dec; 13(12):1856-1861.
-
Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method. Molecules. 2020 Aug 23; 25(17).
-
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV. AIDS. 2020 07 01; 34(8):1258-1260.
-
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. J Infect Public Health. 2020 Sep; 13(9):1210-1223.
-
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2019 09 01; 74(9):2742-2751.
-
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients. Medicine (Baltimore). 2019 Aug; 98(32):e16721.
-
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 08 01; 74(8):2470-2472.